Home › Autoimmune Diseases › North Carolina
Autoimmune Diseases clinical trials in North Carolina
20 studies for Autoimmune Diseases are looking for participants at sites in North Carolina.
Cities in North Carolina
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
- Site Number - 1020, Chapel Hill
- Site Number - 1013, Durham
- Site Number - 1044, Raleigh
RecruitingPhase 3
Ages 18 to 80 · All sexes · Updated Nov 13, 2026 · NCT07039916RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
- University of North Carolina at Chapel Hill - Accepting Adult Patients, Chapel Hill
- Duke University Medical Center - Accepting Young Adults and Juvenile Patients, Durham
RecruitingPhase 2/3
Ages 6 to 75 · All sexes · Updated Nov 13, 2026 · NCT06154252A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
- Duke University Medical Center, Durham
RecruitingPhase 3
Ages 12 and older · All sexes · Updated Nov 12, 2026 · NCT06056297Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
- On Site Clinical Solutions Llc, Charlotte
- Carolina Arthritis Associates, Wilmington
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT07621809Study of PTC844 in Participants With Active Rheumatoid Arthritis
- DJL Clinical Research PLLC, Charlotte
RecruitingPhase 2
Ages 18 to 70 · All sexes · Updated Nov 6, 2026 · NCT07779616A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Duke University Hospital, Durham
- East Carolina University, Greenville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06722235A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- Atrium Health Rheumatology-Southpark, Charlotte
- Duke University Medical Center, Durham
RecruitingPhase 1
Ages 18 to 74 · All sexes · Updated Nov 2, 2026 · NCT07085104A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Duke University Hospital, Durham
- East Carolina University, Greenville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT06948318Evaluation of ETHY-001 for Safety, Tolerability, and Clinical Activity in Thyroid Eye Disease
- Site 113, Wilmington
RecruitingPhase 1Healthy volunteers welcome
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT07885605A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)
- East Carolina University, Greenville
RecruitingPhase 3
Ages 18 to 70 · All sexes · Updated Oct 22, 2026 · NCT07059000Daratumumab in Primary Antiphospholipid Syndrome
- Duke University, Durham
RecruitingPhase 1/2
Ages 18 to 65 · All sexes · Updated Oct 21, 2026 · NCT05671757Environmental Risk Factors for the Anti-synthetase Syndrome
- NIEHS Clinical Research Unit (CRU), Research Triangle Park
RecruitingObservational studyHealthy volunteers welcome
Ages 2 to 100 · All sexes · Updated Oct 16, 2026 · NCT01276470RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
- Duke University, Durham
RecruitingPhase 2/3
Ages 18 to 75 · All sexes · Updated Oct 16, 2026 · NCT06328777RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
- UNC Chapel Hill, Chapel Hill
RecruitingPhase 1/2
Ages 12 to 65 · All sexes · Updated Oct 6, 2026 · NCT06121297A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
- GSK Investigational Site, Durham
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT06572384Study of BHV-1300 in Graves' Disease
- Site-108, Greenville
RecruitingPhase 1
Ages 18 to 65 · All sexes · Updated Jul 31, 2026 · NCT06980649A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
- Duke University, Durham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 14, 2026 · NCT07115745A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- University of North Carolina at Chapel Hill, Chapel Hill
- Levine Children's Hospital, Charlotte
- Duke University Medical Center, Durham
RecruitingObservational study
All ages · All sexes · Updated Jul 6, 2026 · NCT01351545A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
- Duke University Health System, Durham
RecruitingPhase 1
Ages 12 to 70 · All sexes · Updated May 22, 2026 · NCT06308978Maternal Autoimmune Disease Research Alliance (MADRA) Registry
- Duke University, Durham
RecruitingObservational studyHealthy volunteers welcome
All ages · Women · Updated Jan 8, 2026 · NCT03276923From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.